JW Pharmaceutical Corp Cash Flow Conversion Efficiency

Latest as of June 2026: 0.104x

JW Pharmaceutical Corp cash flow conversion efficiency. Based on the latest financial reports, JW Pharmaceutical Corp (001065) has a cash flow conversion efficiency ratio of 0.104x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩42.51 Billion ≈ $28.81 Million USD) by net assets (₩409.94 Billion ≈ $277.81 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of JW Pharmaceutical Corp (2014–2025)

Cash flow conversion efficiency of JW Pharmaceutical Corp from 2014 to 2025. This chart illustrates how JW Pharmaceutical Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 001065 live share price for real-time trading data and today's change.

JW Pharmaceutical Corp Cash Flow Conversion Ratio Explained

JW Pharmaceutical Corp cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

JW Pharmaceutical Corp Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of JW Pharmaceutical Corp ranked by their cash flow conversion efficiency. Also see JW Pharmaceutical Corp (001065) market capitalisation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Jiangsu Yuxing Film Tech SHE:300305	-0.016x
Accent Group Ltd AU:AX1	0.226x
Laser Tek Taiwan Co Ltd TWO:6207	0.037x
J.Jill Inc NYSE:JILL	0.014x
Ratnaveer Precision Engineering Ltd NSE:RATNAVEER	-0.005x
Eastern Pioneer Auto Driving S SHG:603377	0.177x
Wuhan Hanshang Group Co Ltd SHG:600774	0.017x
Cotec Construction JSC VN:CTD	0.269x

Annual Cash Flow Conversion Efficiency for JW Pharmaceutical Corp (2014–2025)

The table below shows the annual cash flow conversion efficiency of JW Pharmaceutical Corp from 2014 to 2025. Review free cash flow generation of JW Pharmaceutical Corp to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩369.37 Billion ≈ $250.32 Million	₩96.40 Billion ≈ $65.33 Million	0.261x	+8.31%
2024-12-31	₩329.49 Billion ≈ $223.29 Million	₩79.39 Billion ≈ $53.80 Million	0.241x	-26.62%
2023-12-31	₩265.44 Billion ≈ $179.89 Million	₩87.16 Billion ≈ $59.07 Million	0.328x	+30.59%
2022-12-31	₩225.76 Billion ≈ $152.99 Million	₩56.76 Billion ≈ $38.47 Million	0.251x	+161.57%
2021-12-31	₩188.54 Billion ≈ $127.77 Million	₩18.12 Billion ≈ $12.28 Million	0.096x	-68.37%
2020-12-31	₩207.47 Billion ≈ $140.60 Million	₩63.05 Billion ≈ $42.73 Million	0.304x	+25.93%
2019-12-31	₩230.09 Billion ≈ $155.93 Million	₩55.53 Billion ≈ $37.63 Million	0.241x	+20.47%
2018-12-31	₩260.11 Billion ≈ $176.27 Million	₩52.11 Billion ≈ $35.31 Million	0.200x	+62.17%
2017-12-31	₩270.78 Billion ≈ $183.50 Million	₩33.45 Billion ≈ $22.67 Million	0.124x	+406.54%
2016-12-31	₩276.31 Billion ≈ $187.25 Million	₩6.74 Billion ≈ $4.57 Million	0.024x	+231.67%
2015-12-31	₩225.41 Billion ≈ $152.75 Million	₩-4.17 Billion ≈ $-2.83 Million	-0.019x	-155.99%
2014-12-31	₩220.02 Billion ≈ $149.11 Million	₩7.28 Billion ≈ $4.93 Million	0.033x	--

About JW Pharmaceutical Corp

KO:001065 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$278.50 Million

₩410.96 Billion KRW

Market Cap Rank

#14890 Global

#477 in Korea

Share Price

₩20450.00

Change (1 day)

-2.15%

52-Week Range

₩19800.00 - ₩29850.00

All Time High

₩88605.96